Literature DB >> 34398668

Exebacase in Addition to Daptomycin against MRSA.

Razieh Kebriaei1, Kyle C Stamper1, Katherine L Lev1, Taylor Morrisette1, Jacinda C Abdul-Mutakabbir1, Raymond Schuch2, Dario Lehoux2, Michael J Rybak1,3,4.   

Abstract

Exebacase is a lysin (cell wall hydrolase) with direct lytic activity against Staphylococcus aureus including methicillin-resistant S. aureus (MRSA). Time-kill analysis experiments illustrated bactericidal activity of exebacase-daptomycin against MRSA strains MW2 and 494. Furthermore, exebacase in addition to daptomycin (10, 6, and 4 mg/kg/day) in a two-compartment ex vivo pharmacokinetic/pharmacodynamic simulated endocardial vegetation model with humanized doses resulted in reductions of 6.01, 4.99, and 2.81 log10 CFU/g (from initial inoculum) against MRSA strain MW2.

Entities:  

Keywords:  S. aureus; daptomycin; exebacase

Mesh：

Substances：

Year:  2021        PMID： 34398668      PMCID： PMC8522749          DOI： 10.1128/AAC.00128-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insights.

Authors:  Razieh Kebriaei; Seth A Rice; Nivedita B Singh; Kyle C Stamper; Logan Nguyen; Zain Sheikh; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2020-10-01       Impact factor: 5.790

2.  Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus.

Authors:  Jun Taek Oh; Cara Cassino; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 3.  Methicillin-resistant Staphylococcus aureus therapy: past, present, and future.

Authors:  Keith A Rodvold; Kevin W McConeghy
Journal:  Clin Infect Dis       Date:  2014-01       Impact factor: 9.079

4.  In vitro activity of Exebacase (CF-301) against clinical Staphylococcus aureus surveillance isolates from the United States, Europe, and Latin America, 2015-2017.

Authors:  Maria Traczewski; Jun Oh; Cara Cassino; Raymond Schuch
Journal:  Diagn Microbiol Infect Dis       Date:  2019-08-01       Impact factor: 2.803

5.  Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography.

Authors:  Dario Lehoux; Arnold S Bayer; Sonia U Shah; Yan Q Xiong; Wessam Abdelhady; James Iwaz; Youngju Pak; Raymond Schuch; Cara Cassino
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

6.  Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase.

Authors:  J M Loeffler; D Nelson; V A Fischetti
Journal:  Science       Date:  2001-12-07       Impact factor: 47.728

7.  Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.

Authors:  I Odenholt-Tornqvist; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

8.  In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.

Authors:  George P Allen; Glenn W Kaatz; Michael J Rybak
Journal:  Int J Antimicrob Agents       Date:  2004-08       Impact factor: 5.283

9.  Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia.

Authors:  Raymond Schuch; Han M Lee; Brent C Schneider; Karen L Sauve; Christina Law; Babar K Khan; Jimmy A Rotolo; Yuki Horiuchi; Daniel E Couto; Assaf Raz; Vincent A Fischetti; David B Huang; Robert C Nowinski; Michael Wittekind
Journal:  J Infect Dis       Date:  2013-11-28       Impact factor: 5.226

10.  Mechanistic Insights Into the Differential Efficacy of Daptomycin Plus β-Lactam Combinations Against Daptomycin-Resistant Enterococcus faecium.

Authors:  Razieh Kebriaei; Kyle C Stamper; Kavindra V Singh; Ayesha Khan; Seth A Rice; An Q Dinh; Truc T Tran; Barbara E Murray; Cesar A Arias; Michael J Rybak
Journal:  J Infect Dis       Date:  2020-10-01       Impact factor: 5.226
View more
  3 in total

Review 1.  Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections.

Authors:  Matthew W McCarthy
Journal:  Drugs R D       Date:  2022-02-17

2.  Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis.

Authors:  Melissa Karau; Suzannah Schmidt-Malan; Jay Mandrekar; Dario Lehoux; Raymond Schuch; Cara Cassino; Robin Patel
Journal:  J Bone Jt Infect       Date:  2022-07-27

3.  Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus epidermidis Strains Isolated from Prosthetic Joint Infections.

Authors:  Aubin Souche; Camille Kolenda; Jordan Teoli; Raymond Schuch; Tristan Ferry; Frédéric Laurent; Jérôme Josse
Journal:  Antimicrob Agents Chemother       Date:  2022-07-11       Impact factor: 5.938
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.